title: The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States.
abstract: Recent United States guidelines recommend one-time birth cohort testing for hepatitis C infection in persons born between 1945 and 1965; this represents a major public health policy undertaking. The purpose of this study was to assess the role of treatment timing and prioritization on predicted cost-effectiveness. The MONARCH hepatitis C lifetime simulation model was used in conjunction with a testing and treatment decision tree to estimate the cost-effectiveness of birth cohort versus risk-based testing incorporating information on age, fibrosis stage and treatment timing. The study used a 1945-1965 birth cohort and included disease progression, testing and treatment-related parameters. Scenario analysis was used to evaluate the impact of hepatitis C virus (HCV) prevalence, treatment eligibility, age, fibrosis stage and timing of treatment initiation on total costs, quality-adjusted life years (QALYs), HCV-related complications and cost-effectiveness. The cost-effectiveness of birth cohort versus risk-based testing was $28,602. Assuming 91% of the population is tested, at least 278,000 people need to be treated for birth cohort testing to maintain cost-effectiveness. Prioritizing treatment toward those with more advanced fibrosis is associated with a decrease in total cost of $7.5 billion and 59,035 fewer HCV-related complications. Total QALYs and complications avoided are maximized when treatment initiation occurs as soon as possible after testing.
  
  
  CONCLUSIONS
  This study confirms that birth cohort testing is, on average, cost-effective. However, this remains true only when enough tested and HCV-positive subjects are treated to generate sufficient cost offsets and QALY gains. Given the practical and financial challenges associated with implementing birth cohort testing, the greatest return on investment is obtained when eligible patients are treated immediately and those with more advanced disease are prioritized.
authors: Centre for Health Economics, Swansea University, Wales, UK; Health Economics & Outcomes Research Ltd., Wales, UK. p.c.mcewan@swansea.ac.uk
authors: Phil
authors: P
authors: McEwan
authors: Thomas
authors: T
authors: Ward
authors: Yong
authors: Y
authors: Yuan
authors: Ray
authors: R
authors: Kim
authors: Gilbert
authors: G
authors: L'italien
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use*; D015331:Cohort Studies; D003362:Cost-Benefit Analysis; D016174:Hepacivirus / Q000472:pathogenicity*; D019698:Hepatitis C, Chronic / Q000175:diagnosis* / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology / Q000473:pathology; D006801:Humans; D008390:Markov Chains; D008403:Mass Screening / Q000191:economics; D008875:Middle Aged; D011159:Population Surveillance / Q000379:methods; D019057:Quality-Adjusted Life Years; D012306:Risk; D014481:United States / Q000453:epidemiology
chemical_list: D000998:Antiviral Agents